Structural characterization of dimethyldithiodenafil and dimethylthiocarbodenafil, analogs of sildenafil

J Pharm Biomed Anal. 2018 Jan 30:148:136-141. doi: 10.1016/j.jpba.2017.09.025. Epub 2017 Sep 23.

Abstract

Two analogs of sildenafil (compounds 1 and 2) were detected in three powder products acquired from online drug markets during an LC-UV-MS analysis of psychotropic drugs. Their structures were established by high-resolution mass spectrometry and NMR spectroscopy. Compound 1 was identified as 5-(5-(3,5-dimethylpiperazine-1-carbonothioyl)-2-ethoxyphenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine-7(6H)-thione and named dimethyldithiodenafil. Compound 2 was identified as 5-(5-(3,5-dimethylpiperazine-1-carbonothioyl)-2-ethoxyphenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one and named dimethylthiocarbodenafil. Compound 1 was subjected to the phosphodiesterase assay (IC50=0.20nM). The three powder products were found to contain 12-19mg of dimethyldithiodenafil and 1.4-3.9mg of dimethylthiocarbodenafil per tube.

Keywords: Dimethyldithiodenafil; Dimethylthiocarbodenafil; HRMS; NMR; PDE assay; X-ray crystallography.

MeSH terms

  • Chromatography, Liquid / methods
  • Magnetic Resonance Spectroscopy / instrumentation
  • Mass Spectrometry / methods
  • Phosphodiesterase Inhibitors / chemistry*
  • Powders / chemistry
  • Psychotropic Drugs / chemistry
  • Pyrimidines / chemistry
  • Sildenafil Citrate / chemistry*

Substances

  • Phosphodiesterase Inhibitors
  • Powders
  • Psychotropic Drugs
  • Pyrimidines
  • Sildenafil Citrate
  • pyrimidine